Genetics and sudden death

Current Opinion in Cardiology

Volumn 28, Issue 3, 2013, Pages 272-281

  Lombardi, Raffaella ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

arrhythmias; cardiomyopathies; genetics; ion channels; sudden cardiac death

Indexed keywords

DESMOCOLLIN; DESMOGLEIN 2; DESMOPLAKIN; PLAKOGLOBIN; PLAKOPHILIN;

ACTION POTENTIAL; BRUGADA SYNDROME; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHANNELOPATHY; CLINICAL PRACTICE; CONGESTIVE CARDIOMYOPATHY; DNA SEQUENCE; GENE MUTATION; GENETIC SCREENING; GENETICS; HEART DISEASE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CARDIOMYOPATHIES; CHANNELOPATHIES; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; LONG QT SYNDROME;

EID: 84876284606     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835fb7f3     Document Type: Review

References (95)

1. George AL Jr. Molecular and genetic basis of sudden cardiac death. J Clin Invest 2013; 123:75-83.
2. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. Oxford: Elsevier; 2007. pp. 933-974.
3. van der Werf C, van Langen IM, Wilde AA. Sudden death in the young: what do we know about it and how to prevent? Circ Arrhythm Electrophysiol 2010; 3:96-104.
4. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011; 364:1643-1656.
5. Wilde AA, Bezzina CR. Genetics of cardiac arrhythmias. Heart 2005; 91:1352-1358.
6. John RM, Tedrow UB, Koplan BA, et al. Ventricular arrhythmias and sudden cardiac death. Lancet 2012; 380:1520-1529.
7. Grace AA, Roden DM. Systems biology and cardiac arrhythmias. Lancet 2012; 380:1498-1508.
8. Dow LE, Lowe SW. Life in the fast lane: mammalian disease models in the genomics era. Cell 2012; 148:1099-1109.
9. Teekakirikul P, Padera RF, Seidman JG, Seidman CE. Hypertrophic cardio-myopathy: translating cellular cross talk into therapeutics. J Cell Biol 2012; 199:417-421.
10. di Gioia CR, Autore C, Romeo DM, et al. Sudden cardiac death in younger adults: autopsy diagnosis as a tool for preventive medicine. Hum Pathol 2006; 37:794-801.
11. Basso C, Carturan E, Pilichou K, et al. Sudden cardiac death with normal heart: molecular autopsy. Cardiovasc Pathol 2010; 19:321-325.
12. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87:524-539.
13. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the Second Consensus Conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670.
14. Puranik R, Chow CK, Duflou JA, et al. Sudden death in the young. Heart Rhythm 2005; 2:1277-1282.
15. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 2012; 9:91-100.
16. McLeod CJ, Bos JM, Theis JL, et al. Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations. Am Heart J 2009; 158:799-805.
17. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085-1092.
18. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010; 40:360-369.
19. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517-2524.
20. Maron BJ, Harris KM, Spirito P, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hyper-trophic cardiomyopathy. Circulation 2006; 114:216-225.
21. Osio A, Tan L, Chen SN, et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 2007; 100:766-768.
22. Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002; 111:943-955.
23. Chen SN, Czernuszewicz G, Tan Y, et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 2012; 111:907-919.
24. Daw EW, Chen SN, Czernuszewicz G, et al. Genome wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 2007; 16:2463-2471.
25. Nagueh SF, Chen S, Patel R, et al. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol 2004; 36:663-673.
26. Lombardi R, Bell A, Senthil V, et al. Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 2008; 79:109-117.
27. Chuan P, Sivaramakrishnan S, Ashley EA, Spudich JA. Cell intrinsic functional effects of the a-cardiac myosin Arg-403-Gln mutation in familial hypertrophic cardiomyopathy. Biophys J 2012; 102:2782-2790.
28. Ruggiero A, Chen SN, Lombardi R, et al. Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calci-neurin activity. Cardiovasc Res 2013; 97:44-54.
29. Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by nonmyocyte proliferation and requires Tgf. J Clin Invest 2010; 120:3520-3529.
30. Shephard R, Semsarian C. Role of animal models in HCM research. Cardio-vasc Transl Res 2009; 2:471-482.
31. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2001; 109:1013-1020.
32. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317-324.
33. Senthil V, Chen SN, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardio-myopathy. Circ Res 2005; 97:285-292.
34. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103:789-791.
35. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006; 47:827-834.
36. Lombardi R, Rodriguez G, Chen SN, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 2009; 119:1398-1407.
37. Bauersachs J, Stork S, Kung M, et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007; 37:852-859.
38. Nagueh SF, Lombardi R, Tan Y, et al. Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest 2010; 4011:976-983.
39. Araujo AQ, Arteaga E, Ianni BM, et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopa-thy. Am J Cardiol 2005; 96:1563-1567.
40. Yamazaki T, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J 2007; 48:715-724.
41. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761-2796.
42. Lombardi R, Marian AJ. Molecular genetics and pathogenesis of arrhythmo-genic right ventricular cardiomyopathy: a disease of cardiac stem cells. Pediatr Cardiol 2011; 32:360-365.
43. Sen-Chowdhry S, McKenna WJ. Sudden cardiac death in the young: a strategy for prevention by targeted evaluation. Cardiology 2006; 105:196-206.
44. Marcus FI, Abidov A. Arrhythmogenic right ventricular cardiomyopathy 2012: diagnostic challenges and treatment. J Cardiovasc Electrophysiol 2012; 23:1149-1153.
45. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmo-plantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355:2119-2124.
46. Kaplan SR, Gard JJ, Carvajal-Huerta L, et al. Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc Pathol 2004; 13:26-32.
47. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002; 71:1200-1206.
48. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004; 36:1162-1164.
49. van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2006; 113:1650-1658.
50. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113:1171-1179.
51. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmo-collin-2. Am J Hum Genet 2006; 79:978-984.
52. Beffagna G, Occhi G, Nava A, et al. Regulatory mutations in transforming growth factor-beta 3 gene cause arrhythmogenic right ventricular cardiomyo-pathy type 1. Cardiovasc Res 2005; 65:366-373.
53. Merner ND, Hodgkinson KA, Haywood AFM, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the tmem 43 gene. Am J Hum Genet 2008; 82:809-821.
54. Garcia-Gras E, Lombardi R, Giocondo MJ, et al. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116:2012-2021.
55. Lombardi R, Dong J, Rodriguez G, et al. Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmo-genic right ventricular cardiomyopathy. Circ Res 2009; 104:1076-1084.
56. Lombardi R, Cabreira-Hansen MG, Bell A, et al. Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2011; 109: 1342-1353.
57. Yang Z, Bowles NE, Scherer SE, et al. Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res 2006; 99:646-655.
58. Beffagna G, De Bortoli M, Nava A, et al. Missense mutations in desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. BMC Med Genet 2007; 8:65.
59. Pilichou K, Remme CA, Basso C, et al. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. J Exp Med 2009; 206:1787-1802.
60. Swope D, Li J, Radice GL. Beyond cell adhesion: the role of armadillo proteins in the heart. Cell Signal 2013; 25:93-100.
61. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289:950-953.
62. Rizzo S, Lodder EM, Verkerk AO, et al. Intercalated disc abnormalities, reduced Na(+) current density, and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes. Cardiovasc Res 2012; 95:409-418.
63. Cerrone M, Noorman M, Lin X, et al. Sodium current deficit and arrhythmo-genesis in a murine model of plakophilin-2 haploinsufficiency. Cardiovasc Res 2012; 95:460-468.
64. Oxford EM, Musa H, Maass K, et al. Connexin 43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells. Circ Res 2007; 101:703-711.
65. Sato PY, Musa H, Coombs W, et al. Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes. Circ Res 2009; 105:523-526.
66. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108:3084-3091.
67. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2011; 57:1641-1649.
68. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807-1816.
69. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 2013; 123:19-26.
70. Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J 2012; 33:296-304.
71. Bowles NE, Bowles KR, Towbin JA. The 'final common pathway' hypothesis and inherited cardiovascular disease: the role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000; 25:168-175.
72. Debold EP, Schmitt JP, Patlak JB, et al. Hypertrophic and dilated cardiomyo-pathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 2007; 293:H284-H291.
73. Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarco-glycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106:655-662.
74. Fukuda N, Terui T, Ishiwata S, Kurihara S. Titin-based regulations of diastolic and systolic functions of mammalian cardiac muscle. J Mol Cell Cardiol 2010; 48:876-881.
75. Haghighi K, Kolokathis F, Gramolini AO, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 2006; 103:1388-1393.
76. Lammerding J, Schulze PC, Takahashi T, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113:370-378.
77. Simon DN, Wilson KL. The nucleoskeleton as a genome-associated dynamic 'network of networks'. Nat Rev Mol Cell Biol 2011; 12:695-708.
78. Refaat MM, Lubitz SA, Makino S, et al. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm 2012; 9:390-396.
79. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009; 81:412-419.
80. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 2012; 5:868-877.
81. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120:1761-1767.
82. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007; 49:240-246.
83. Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type-1 long-QT syndrome. Circulation 2012; 125:1988-1996.
84. Ackerman MJ, Mohler PJ. Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel-and transporter-associated proteins. Circ Res 2010; 107:457-465.
85. Itoh H, Shimizu W, Hayashi K, et al. Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multi-center study. Heart Rhythm 2010; 7:1411-1418.
86. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363:1397-1409.
87. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471:225-229.
88. Berne P, Brugada J. Brugada syndrome 2012. Circ J 2012; 76:1563-1571.
89. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations intheSCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7:33-46.
90. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012; 59:37-45.
91. Pflaumer A, Davis AM. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia. Heart, Lung and Circ 2012; 21:96-100.
92. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54:2065-2074.
93. Venetucci L, Denegri M, Napolitano C, Priori SG. Inherited calcium channelo-pathies in the pathophysiology of arrhythmias. Nat Rev Cardiol 2012; 9:561-575.
94. Liu N, Ruan Y, Denegri M, et al. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C±) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 2011; 50:214-222.
95. Jung CB, Moretti A, Mederos YSM, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2012; 4:180-191.